SCM
SVA

Stevens Capital Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Stevens Capital Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,639
Closed -$53K – 1422
2015
Q1 		$53K Sell
10,639
-7,182
-40% -$35.4K ﹤0.01% 948
2014
Q4 		$93K Sell
17,821
-4,564
-20% -$23.3K ﹤0.01% 936
2014
Q3 		$108K Buy
22,385
+5,430
+32% +$29.1K ﹤0.01% 924
2014
Q2 		$96K Buy
+16,955
New +$103K ﹤0.01% 1007

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Stevens Capital Management's SVA Position: Q2 2015 in Review

Stevens Capital Management sold out of Sinovac Biotech, Ltd (SVA) in Q2 2015, closing a stake of 10,639 shares — an estimated $53K sold.

Stevens Capital Management first reported a position in SVA in Q2 2014 and held it in 4 quarters. The position peaked at $108K in Q3 2014. 37 funds tracked by Wall St. Rank hold SVA as of Q2 2015.

  • Stevens Capital Management reported no remaining Sinovac Biotech, Ltd position as of Q2 2015 after selling out during the quarter.
  • Stevens Capital Management sold 10,639 Sinovac Biotech, Ltd shares in Q2 2015, an estimated $53K.
  • Stevens Capital Management first reported a position in Sinovac Biotech, Ltd in Q2 2014 and held it in 4 quarters.
  • Stevens Capital Management's Sinovac Biotech, Ltd position peaked at $108K in Q3 2014.
  • 37 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2015.

Based on Stevens Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.